Neuren Pharmaceuticals Ltd has released a press release.
DAYBUE STIX now broadly available in US for Rett syndrome
Earlier from Neuren Pharmaceuticals
- Acadia confirms plan to request CHMP re-examination
- 2025 royalty income A$65m, profit after tax A$30m
- Appendix 4E and 2025 full year accounts
- Acadia reports DAYBUE net sales for 2025 and 2026 guidance